Silence Therapeutics plc (SLNCF)
| Market Cap | 328.75M |
| Revenue (ttm) | 25.83M |
| Net Income (ttm) | -64.54M |
| Shares Out | n/a |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 1,012 |
| Open | 1.800 |
| Previous Close | 1.800 |
| Day's Range | 1.800 - 1.800 |
| 52-Week Range | 0.499 - 5.450 |
| Beta | 1.34 |
| RSI | 51.93 |
| Earnings Date | Nov 7, 2025 |
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, includin... [Read more]
Financial Performance
In 2024, Silence Therapeutics's revenue was $43.26 million, an increase of 36.71% compared to the previous year's $31.64 million. Losses were -$45.31 million, -16.45% less than in 2023.
Financial StatementsNews
Silence Therapeutics: Divesiran Targets High-Burden PV
Silence Therapeutics is advancing its lead RNAi drug, divesiran, for polycythemia vera, with a fully enrolled Phase 2 trial and results expected in Q3 2026. SLN boasts a strong cash position ($100M+),...
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that...
Silence Therapeutics plc Non-GAAP EPS of -$0.15, revenue of $0.16M
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it h...
Silence Therapeutics (SLN) Receives Reiterated Buy Rating from HC Wainwright | SLN Stock News
Silence Therapeutics (SLN) Receives Reiterated Buy Rating from HC Wainwright | SLN Stock News
Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Silence Therapeutics to Participate in September Investor Conferences
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Silence (SLN) Q2 Revenue Drops 71%
Silence Therapeutics Plc (SLN -1.32%), a biotechnology company focused on developing RNA interference (RNAi) therapeutics, released its second quarter results on August 7, 2025. The company reported G...
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) th...
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript
Silence Therapeutics plc (NASDAQ:SLN) Q4 2024 Earnings Call February 27, 2025 8:00 AM ETCompany ParticipantsGem Hopkins - Vice President, Investor Relations...
Silence Therapeutics plc 2024 Q4 - Results - Earnings Call Presentation
Silence Therapeutics PLC (SLNCF) Reports Full Year 2024 Financial Results with Strong Cash ...
Silence Therapeutics PLC (SLNCF) Reports Full Year 2024 Financial Results with Strong Cash Position and Strategic Pipeline Advancements
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Redmile Group, LLC Acquires Significant Stake in Silence Therapeutics PLC
Redmile Group, LLC Acquires Significant Stake in Silence Therapeutics PLC
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Lombard Odier Asset Management's Strategic Acquisition in Silence Therapeutics PLC
Lombard Odier Asset Management's Strategic Acquisition in Silence Therapeutics PLC
Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints
Silence Therapeutics: Simply No Match For Its Orally Dosed Rival (Downgrade)
Top 3 Health Care Stocks That May Explode In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go ...
Top 3 Health Care Stocks That May Explode In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.